[Progress in the diagnosis and treatment of Castleman disease].
作者信息
Liu H L, Fan L, Li J Y
机构信息
Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):697-700. doi: 10.3760/cma.j.issn.0253-2727.2020.08.017.
Abstract
摘要
相似文献
1
[Progress in the diagnosis and treatment of Castleman disease].[Castleman病的诊断与治疗进展]
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):697-700. doi: 10.3760/cma.j.issn.0253-2727.2020.08.017.
2
Castleman-Kojima disease in a South Asian adolescent.一名南亚青少年患卡斯特曼-小岛病。
J Clin Exp Hematop. 2014;54(2):163-6. doi: 10.3960/jslrt.54.163.
3
Preoperative embolization as an adjunct to the operative management of mediastinal Castleman disease.术前栓塞作为纵隔Castleman病手术治疗的辅助手段。
J Pediatr Surg. 2003 Sep;38(9):E21-3. doi: 10.1016/s0022-3468(03)00421-4.
4
Diagnosis and Management of Castleman Disease.《卡斯特曼病的诊断与治疗》。
J Natl Compr Canc Netw. 2019 Nov;17(11.5):1417-1419. doi: 10.6004/jnccn.2019.5037.
5
[The consensus of the diagnosis and treatment of Castleman disease in China (2021)].《中国Castleman病诊断和治疗专家共识（2021年版）》
Zhonghua Xue Ye Xue Za Zhi. 2021 Jul 14;42(7):529-534. doi: 10.3760/cma.j.issn.0253-2727.2021.07.001.
6
Diagnosis and management of Castleman disease.Castleman病的诊断与管理
Cancer Control. 2014 Oct;21(4):266-78. doi: 10.1177/107327481402100403.
7
Unicentric Castleman Disease.单中心Castleman病
Hematol Oncol Clin North Am. 2018 Feb;32(1):65-73. doi: 10.1016/j.hoc.2017.09.006.
8
[Castleman disease].[卡斯特曼病]
An Pediatr (Barc). 2005 Jul;63(1):68-71. doi: 10.1157/13076770.
9
A case of idiopathic multicentric Castleman disease presenting with diffuse lung cysts: how to evaluate treatment response?一例以弥漫性肺囊肿为表现的特发性多中心Castleman病：如何评估治疗反应？
Ann Hematol. 2020 Jun;99(6):1401-1402. doi: 10.1007/s00277-020-04030-5. Epub 2020 May 7.
10
Castleman Disease.卡斯特曼病
Hematol Oncol Clin North Am. 2018 Feb;32(1):xiii-xiv. doi: 10.1016/j.hoc.2017.10.001.
引用本文的文献
1
[Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report].[西妥昔单抗和托珠单抗序贯治疗儿童特发性多中心Castleman病：一例报告]
Zhongguo Dang Dai Er Ke Za Zhi. 2025 May 15;27(5):613-617. doi: 10.7499/j.issn.1008-8830.2412050.
2
[Castleman disease in the parapharyngeal space: a case report].[咽旁间隙Castleman病：一例报告]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024 Dec;38(12):1187-1189. doi: 10.13201/j.issn.2096-7993.2024.12.019.
3
A rare case report of hyaline-vascular type Castleman disease in the presacral region.骶前区透明血管型Castleman病的罕见病例报告。
Front Oncol. 2024 Aug 26;14:1434542. doi: 10.3389/fonc.2024.1434542. eCollection 2024.
4
Novel Molecular Therapies and Genetic Landscape in Selected Rare Diseases with Hematologic Manifestations: A Review of the Literature.选定具有血液学表现的罕见疾病中的新型分子疗法和遗传图谱：文献复习。
Cells. 2023 Jan 30;12(3):449. doi: 10.3390/cells12030449.
5
[Analysis of the clinical characteristics and prognosis of 20 patients with multicenter Castleman disease].[20例多中心Castleman病患者的临床特征及预后分析]
Zhonghua Xue Ye Xue Za Zhi. 2021 Jun 14;42(6):510-513. doi: 10.3760/cma.j.issn.0253-2727.2021.06.012.
本文引用的文献
1
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.在 IL-6 阻断治疗抵抗性特发性多中心 Castleman 病中鉴定和靶向致病性 PI3K/AKT/mTOR 信号通路。
J Clin Invest. 2019 Aug 13;129(10):4451-4463. doi: 10.1172/JCI126091.
2
Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.病毒组捕获测序不能在局灶性和特发性多中心 Castleman 病中识别出活跃的病毒感染。
PLoS One. 2019 Jun 26;14(6):e0218660. doi: 10.1371/journal.pone.0218660. eCollection 2019.
3
Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?TAFRO 综合征是否为特发性多中心 Castleman 病的一个亚型？
Am J Hematol. 2019 Sep;94(9):975-983. doi: 10.1002/ajh.25554. Epub 2019 Jun 21.
4
Treatment and outcome of Unicentric Castleman Disease: a retrospective analysis of 71 cases.孤立性Castleman 病的治疗和转归：71 例回顾性分析。
Br J Haematol. 2019 Jul;186(2):269-273. doi: 10.1111/bjh.15921. Epub 2019 Apr 23.
5
Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease.采用口服沙利度胺-环磷酰胺-泼尼松治疗特发性多中心 Castleman 病的 2 期研究。
Blood. 2019 Apr 18;133(16):1720-1728. doi: 10.1182/blood-2018-11-884577. Epub 2019 Feb 13.
6
Recurrent PDGFRB mutations in unicentric Castleman disease.单中心Castleman病中的复发性血小板衍生生长因子受体B（PDGFRB）突变
Leukemia. 2019 Apr;33(4):1035-1038. doi: 10.1038/s41375-018-0323-6. Epub 2019 Jan 3.
7
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.特发性多中心 Castleman 病抗 IL-6 单克隆抗体治疗（西妥昔单抗）反应的预测因素：Ⅱ期临床试验数据的二次分析。
Br J Haematol. 2019 Jan;184(2):232-241. doi: 10.1111/bjh.15588. Epub 2018 Sep 11.
8
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.特发性多中心 Castleman 病的国际、循证共识治疗指南。
Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.
9
Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.利妥昔单抗联合治疗方案治疗特发性多中心 Castleman 病的疗效。
Ann Hematol. 2018 Sep;97(9):1641-1647. doi: 10.1007/s00277-018-3347-0. Epub 2018 May 7.
10
Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.血浆蛋白质组学鉴定出特发性多中心 Castleman 病中的“趋化因子风暴”。
Am J Hematol. 2018 Jul;93(7):902-912. doi: 10.1002/ajh.25123. Epub 2018 May 16.
Zotero 插件